Evercore ISI analyst Vijay Kumar has maintained their bullish stance on TMO stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vijay Kumar has given his Buy rating due to a combination of factors including Thermo Fisher’s recent financial performance and future growth prospects. The company reported a strong second quarter with a 2% organic growth that exceeded expectations by approximately 100 basis points. Key segments such as Life Science Solutions and Lab Products & Services showed positive growth, while the overall gross margins aligned with expectations, and operating margins slightly surpassed them.
Looking ahead, Thermo Fisher’s guidance for fiscal year 2025 indicates steady organic growth and an increase in earnings per share, supported by cost-saving measures. The company anticipates a gradual recovery in the Pharma and Biotech sectors, despite some ongoing softness in the US and China markets. Over the mid to long term, Thermo Fisher is expected to achieve consistent organic growth, driven by strong performance in its Biopharma services and bioproduction segments, which have shown promising bookings growth.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $485.00 price target.